MiNK Therapeutics (INKT)
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, of...
- Open
- 12.240
- High
- 11.920
- Low
- 11.530
- Prev. Close
- 12.200
- Volume
- 6.61K
- Turnover
- 77.33K
- Avg Price
- 11.693
- Bid/Ask Ratio
- -66.67%
- Amplitude
- 3.20%
- 52wk High
- 16.980
- Volume Ratio
- 0.79
- Turnover Ratio
- 0.34%
MiNK Therapeutics Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$39.00233.33%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Aug 18 at 04:44 AM
Lyft's Booking Boom Clouded by Short Seller Drama as Dominion's Mega-Merger Faces Pushback
- TradingKey · Aug 14 at 03:24 AM
MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial Advances
- Quartr · Aug 13 at 06:42 AM
INKT: Phase 2 trial of agenT-797 showed early clinical benefit; cash at $8.8M, net loss narrowed
- PUBT · Aug 6 at 11:01 AM
MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trial
- PUBT · Aug 6 at 07:19 AM
Mink Therapeutics to report Q2 results, host conference call and webcast
- Market Beat · Aug 6 at 01:56 AM
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday
